Is it Time to Dump AEterna Zentaris Inc. (AEZS) Stock After it Has Fallen 2.90% in a Week?

The market has been down on AEterna Zentaris Inc. (AEZS) stock recently. AEZS gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

AEterna Zentaris Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AEZS!

See Full AEZS Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AEZS Stock Today?

AEterna Zentaris Inc. (AEZS) stock is trading at $2.01 as of 1:34 PM on Wednesday, Mar 27, a rise of $0.01, or 0.5% from the previous closing price of $2.00. Volume today is less active than usual. So far 13,055 shares have traded compared to average volume of 21,042 shares. The stock has traded between $1.97 and $2.09 so far today. To screen for more stocks like AEterna Zentaris Inc. click here.

More About AEterna Zentaris Inc.

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. Click Here to get the full Stock Report for AEterna Zentaris Inc. stock.